St Vincent's Hospital Sydney

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer

ABSTRACT High‐risk estrogen receptor positive (ER+) early breast cancer (EBC) is managed with endocrine therapies and cyclin‐dependent kinase (CDK) 4/6 inhibitors, although no standard molecular markers clinically identify these tumors. CDK1 lies immediately downstream of CDK4/6...

hpci improves reproducibility of computational biology research by integrating Continuous Integration with High Performance Computing clusters

Abstract Motivation The reproducibility crisis in bioinformatics and computational biology can be mitigated by using Continuous Integration (CI), a proven software engineering practice, to automate the testing of analysis pipelines and models. However, the adoption of CI in bioin...

Key considerations for window of opportunity trials and preoperative endocrine therapy in breast cancer

Window of opportunity (WOO) trials are short, pre-surgical trials which aim to evaluate novel therapeutic strategies and answer biological and mechanistic questions. Despite their relative simplicity, their conduct can be challenging. This Perspectives Article considers key facto...

Assessing and Addressing Frailty in Candidates for Lung Transplantation: An ISHLT Consensus Statement.

The ISHLT Consensus document for the selection of lung transplant candidates recommends frailty assessment as part of a comprehensive candidacy evaluation. Missing from this and other recent consensus documents were practical recommendations on which frailty measures to consider...

Patient perspectives on cardioprotective medication during breast cancer treatment

Cardiotoxicity remains a key concern of HER2-directed therapies, with no proven prevention strategies. The success of cardioprotective interventions will depend not only on efficacy, but on patient acceptability, an underexplored determinant of trial participation and clinical im...

On-demand therapies–emergency medication or daily routine?

Abstract Fluctuations represent a major therapeutic challenge in Parkinson’s disease (PD) and become increasingly prevalent with disease progression. While oral and device-aided therapies (DAT) improve symptom control, patients continue to experience disabling OFF episodes, in pa...

ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand

BACKGROUND: Despite pre-emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients. AIMS AND METH...

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial

Abstract Background Polypharmacy in chronic kidney disease (CKD) is substantial. Clinicians and patients are often reluctant to add medications to already complex regimens, partly due to concerns about diminishing efficacy and increased adverse effects. We assessed whether effica...

Novel chimeric PD-L1::PD-L2 fusion and immune evasion in lymphoma

We report a novel in-frame CD274::PDCD1LG2 fusion in primary mediastinal B-cell lymphoma. Functional studies using expression constructs and CRISPR-engineered lymphoma cells confirmed formation of a PD-L1::PD-L2 chimeric protein and marked upregulation of PD-L1 surface expression...

Model 1b analytical performance specifications – report on the Prague 2025 workshop

diagnostic medical devices (IVD MD) meet regulatory and quality standards before market release; for external quality assurance assessments; for quality control, monitoring reagent lot-to-lot variability, and allowing preanalytical variation assessments in labs; and for guiding p...

Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy

Optimal dosing of vancomycin in critically ill patients receiving renal replacement therapy (RRT) is uncertain due to high pharmacokinetic variability. We aimed to develop individualised vancomycin dosing recommendations that optimise efficacy while minimising toxicity. Prospecti...